In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Research & Development

New data show that European pharma innovation is being edged into third place by innovation coming from the US and the new powerhouse of research, China.


Investment In New Products: Looking Beyond The R&D Line

Johnson & Johnson and Roche lead the most recent Scrip 100 ranking for R&D spend, but a look beyond investment in internal development highlights a big year for Pfizer and Bristol Myer Squibb.

The Future Of Obesity

Novo Nordisk and Eli Lilly are duking it out in the market, but dozens of competitors are waiting in the wings.

Examining The Clinical Trials Landscape

In a post-pandemic world, the evolving landscape of clinical trials just got more complex. The year 2022 was one of many adjustments given the incidence of lower trial initiations. The health care industry endured the impacts of geopolitical conflicts, curbed growth in China and stagflation in major markets.

The New Antibodies Revolutionizing Medicine

Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.

Chapter sponsored by:

Ipsen logo

Navigating Innovation
To Deliver For Patients

Christelle Huguet

Christelle Huguet,
Head of R&D at Ipsen, discusses how External Innovation is central to Ipsen’s R&D strategy and provides a spotlight on Rare Disease,
where the portfolio has seen strong movement in 2023.

Download Now

About Ipsen

Ipsen are dedicated to delivering transformative medicines in Oncology, Rare Disease and Neuroscience.

Learn More »

Outlook 2024 e-Book

Outlook 2024 cover

Download a PDF copy of the Outlook 2024 collection, including Scrip 100 league tables.

ACCESS NOW
UsernamePublicRestriction

Register